Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Inhibin-A Augments Plgf and the Sflt-1 / Plgf Ratio in the Prediction of Preeclampsia and / or Fgr near Delivery

Version 1 : Received: 31 December 2020 / Approved: 31 December 2020 / Online: 31 December 2020 (14:23:21 CET)

How to cite: Sharabi-Nov, A.; Premru Sršen, T.; Kumar, K.; Fabjan Vodušek, V.; Fabjan, T.; Tul, N.; Meiri, H.; Nicolaides, K.H.; Osredkar, J. Inhibin-A Augments Plgf and the Sflt-1 / Plgf Ratio in the Prediction of Preeclampsia and / or Fgr near Delivery. Preprints 2020, 2020120819 (doi: 10.20944/preprints202012.0819.v1). Sharabi-Nov, A.; Premru Sršen, T.; Kumar, K.; Fabjan Vodušek, V.; Fabjan, T.; Tul, N.; Meiri, H.; Nicolaides, K.H.; Osredkar, J. Inhibin-A Augments Plgf and the Sflt-1 / Plgf Ratio in the Prediction of Preeclampsia and / or Fgr near Delivery. Preprints 2020, 2020120819 (doi: 10.20944/preprints202012.0819.v1).

Abstract

Objective: We previously provided evidence to confirm that soluble Fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and their ratio, are useful tools to direct the management of preeclampsia (PE), fetal growth restriction (FGR), and PE+FGR near delivery. In this study we examine the potential additive value of Inhibin-A, a hormone marker of the transforming growth factor family. Methods: We used a cohort of 125 pregnant women enrolled near delivery at clinics of the University Medical Center of Ljubljana, Slovenia. There were 31 cases of PE, 16 of FGR, 42 of PE+FGR, 15 iatrogenic preterm delivery (PTD), and 21 unaffected controls with delivery of a healthy baby at term. Cases delivered before 34 weeks’ gestation included 13 of PE, 12 of FGR, 22 of PE+FGR, and 6 of PTD. We recorded demographic characteristics and medical history and the levels of PlGF, sFlt-1 and Inhibin-A. The predictive accuracy of each biomarker, their ratios, and combinations was estimated from areas under the curve (AUC) of Receiver Operating Characteristics (ROC) curves. We estimated accuracy by the continuous marker model and a cut-off model. Results: Combining Inhibin-A with PlGF or with the sFlt-1 / PlGF ratio showed a 10-20% increase in AUCs and 5-15% increase in the detection rate, at 10% false positive rate, of PE, and a lower, but significant, increase for PE+FGR but not for FGR alone. The use of a cut-off model was adequate, although a bit higher accuracy was obtained from the continuous model. Highest correlation was found for PlGF with all three complications. Conclusion: Inhibin-A improves the accuracy of predicting PE and PE+FGR provided by the angiogenic markers alone, bringing the results to a diagnostic level, thus assisting in directing clinical management. Inhibin-A had no added value for the accuracy of predicting FGR alone.

Subject Areas

Preeclampsia; Fetal growth restriction; sFlt-1; Inhibin-A; Placental growth factor

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.